2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Snapshot: Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), a key signalling molecule produced in the hypothalamus [1]. It triggers the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [2]. Clinically, it is used to assess hypothalamic-pituitary function and to induce ovulation in select cases [2].
Gonadorelin peptide is a low-weight, synthetic analogue structurally identical to the body’s endogenous GnRH released by the hypothalamus [1]. It acts as a central regulator of the hypothalamic-pituitary-gonadal axis, stimulating pituitary release of LH and FSH to control reproduction, sex hormone production, and fertility [1].
It binds to LHRH receptors on pituitary gonadotroph cells to stimulate the release of LH and FSH; with continuous exposure, these receptors become desensitized [3]. Clinically, it is used to assess hypothalamic–pituitary function and in select cases of hypothalamic amenorrhea [3]. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) and can be detected in urine [4].
Gonadorelin has broad clinical applications across reproductive medicine, endocrinology, and gynecology [5]. By providing direct stimulation to the hypothalamic-pituitary-gonadal axis, it has shown benefits for restoring physiological hormone signalling and modulating it for diagnostic or therapeutic purposes [5].
Gonadorelin has been clinically explored to induce ovulation and support fertility interventions, assess endocrine function, manage hormone-sensitive conditions, and treat gynecologic disorders, including endometriosis and uterine fibroids [5]. It has also been studied for contraceptive use and for protecting ovarian function during chemotherapy [6].
Evidence suggests gonadorelin can support ovulation through restoration or modulation of the normal hypothalamic-pituitary axis signalling [7]. By mimicking endogenous GnRH, gonadorelin can normalize LH and FSH release, re-establish physiologic GnRH pulsatility, and promote ovulatory function in hyperandrogenic disorders and gonadotropin imbalance [1].
Experimental models demonstrate meaningful ovulation rates with gonadorelin compared to controls, supporting its role as an effective ovulation-induction agent [8]. It works via triggering a pituitary LH surge that promotes dominant follicle ovulation and corpus luteum formation [8]. In one animal model, gonadorelin increased sex steroid levels and induced ovulation in 67% of treated females, while no control subjects ovulated [9].
Gonadorelin modulates the hypothalamic-pituitary-gonadal axis to regulate sex hormone signalling across a range of conditions [10]. When administered repeatedly, it can induce a reversible pituitary desensitization, causing temporary suppression of gonadotropin signalling to sex organs [10].
Clinically, gonadorelin has shown benefits in:
Animal studies also show benefits. A large field trial involving dairy cows with cystic ovarian disease reported resolution rates exceeding 90% after a single treatment, regardless of timing postpartum, highlighting the reliability of its hormonal action [16].
Gonadorelin is thought to improve fertility treatment outcomes by stabilizing pituitary signalling during controlled ovarian stimulation [17]. By suppressing erratic or premature LH release, gonadorelin helps to prevent premature ovulation and hormone fluctuations that can disrupt cycle timing [17]. This control can increase the proportion of adequate stimulation cycles, reduce cycle cancellation, and may allow greater flexibility in scheduling stimulation and optimizing IVF protocols.
Animal models have found that adding gonadorelin can support pregnancy outcomes. A large cattle study in Brazil found that administering gonadorelin at the time of fixed-time embryo transfer significantly improved conception rates at both 30 and 60 days of gestation compared with untreated controls [17]. Treated animals also showed reduced pregnancy loss, indicating that GnRH analogue use can enhance embryo transfer success, even under less favorable conditions [17].
There are several known side effects of gonadorelin peptide, with many largely related to predictable, reversible hypoestrogenic states. The most common are mild, including abdominal discomfort, short-lasting flushing, headaches, light-headedness, and nausea [18]. Following repeated doses, there have been reports in the literature of difficulty breathing, continuous flushing, and rapid heart rate, although they are rare [18]. Injection site reactions can occur, as well as hormonal side effects from estrogen depletion, including hot flashes, vaginal dryness, and reversible trabecular bone resorption [18, 2].
References
1 Torrini, F., Scarano, S., Palladino, P. and Minunni, M. (2023) Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin. J. Pharm. Biomed. Anal., Elsevier BV 228, 115312
2 Chrisp, P. and Goa, K. L. (1990) Nafarelin: A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs, Springer Nature 39, 523–551
3 National Cancer Institute. (2020, February 7) Recombinant Gonadorelin. Definitions, Qeios https://doi.org/10.32388/9g8tac
4 The Prohibited List. World Anti Doping Agency https://www.wada-ama.org/en/prohibited-list
5 Conn, P. M. and Crowley, W. F., Jr. (1994) Gonadotropin-releasing hormone and its analogs. Annu. Rev. Med., Annual Reviews 45, 391–405
6 Lambertini, M., Moore, H. C. F., Leonard, R. C. F., Loibl, S., Munster, P., Bruzzone, M., et al. (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J. Clin. Oncol., J Clin Oncol 36, 1981–1990
7 Picard-Hagen, N., Lhermie, G., Florentin, S., Merle, D., Frein, P. and Gayrard, V. (2015) Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology, Elsevier BV 84, 177–183
8 Lima, F. S., Ayres, H., Favoreto, M. G., Bisinotto, R. S., Greco, L. F., Ribeiro, E. S., et al. (2011) Effects of gonadotropin-releasing hormone at initiation of the 5-d timed artificial insemination (AI) program and timing of induction of ovulation relative to AI on ovarian dynamics and fertility of dairy heifers. J. Dairy Sci., American Dairy Science Association 94, 4997–5004
9 Oliveira, R. G. de S., de Morais, I. S., Paixão, R. V., Bandeira, I. C., Duncan, W. L. P. and O’Sullivan, F. L. de A. (2025) Effects of gonadorelin on gonadotropin expression, plasma sex steroid concentrations and ovarian follicle dynamics in mature tambaqui (Colossoma macropomum). Comp. Biochem. Physiol. B Biochem. Mol. Biol., Elsevier BV 279, 111126
10 Wang, X., Zhang, Z. X., Chen, J., Fu, D., Du, M., Chen, Y., et al. (2025) Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. Endocr. Connect., Bioscientifica Ltd 14 https://doi.org/10.1530/EC-24-0655
11 Barrett, R., Barrett, R., Dhar, K. and Birch, B. (2021) Gonadorelins adherence in prostate cancer: A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020). BJUI Compass, Wiley 2, 419–427
12 Huerta-Reyes, M., Maya-Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo-Marin, J.-C., et al. (2019) Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front. Oncol., Frontiers Media SA 9, 943
13 Shao W.-M., Bai W.-J., Chen Y.-M., Liu L. and Wang Y.-J. (2014) Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review. Beijing Da Xue Xue Bao, Beijing Da Xue Xue Bao Yi Xue Ban 46, 642–645
14 Foye, W. O. (2008) Foye’s principles of medicinal chemistry, Lippincott williams & wilkins
15 Schulenburg-Brand, D., Gardiner, T., Guppy, S., Rees, D. C., Stein, P., Barth, J., et al. (2017) An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep., Springer Berlin Heidelberg 36, 99–107
16 Hooijer, G. A., Frankena, K., Valks, M. M. and Schuring, M. (1999) Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. Vet. Q., Informa UK Limited 21, 33–37
17 Defensor, M. L., Faria, A. C. F., Marques, F. L. A., Cadima, G. P., Mafra, M. O. and Santos, R. M. dos. (2021, September 13) Effect of treatment with gonadoreline at the embryo transfer on pregnancy outcomes in bovine. Research Square https://doi.org/10.21203/rs.3.rs-765941/v1
18 (2024, February 15) Gonadorelin: Indications, Side Effects, Warnings. Drugs.com https://www.drugs.com/cdi/gonadorelin.html
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Gonadorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
The facts state that gonadorelin is identical to native gonadotropin-releasing hormone (GnRH). In humans and rhesus macaques, two molecular forms of GnRH have been identified, GnRH-I and GnRH-II, which appear to differentially contribute to the regulation of the menstrual cycle. The facts describe GnRH-I as one of these two forms but do not directly link gonadorelin to either form. The source notes that native GnRH is expensive and often unavailable, which motivated the search for an alternative stimulation agent.
The review states that gonadorelin was approved by the U.S. Food and Drug Administration. The same review states that gonadorelin is no longer manufactured.
The facts describe gonadorelin's availability as limited but do not give a reason for this. The paper reports that this limited availability has led to increased use of subcutaneous triptorelin to diagnose central precocious puberty, and that studies validating its diagnostic value remain limited. The paper also describes native GnRH, the hormone gonadorelin is identical to, as expensive and often unavailable.
Yes, in a retrospective human study, gonadorelin was used to test girls referred for suspected precocious puberty. Of the 341 girls evaluated, 239 underwent the gonadorelin test and 102 underwent the triptorelin test. In that study, all patients with central precocious puberty were identified 60 minutes after gonadorelin administration. By comparison, approximately 10% of patients with central precocious puberty were diagnosed only at 90 and 120 minutes after triptorelin administration. In these girls, gonadorelin and triptorelin raised luteinizing hormone to similar peak levels, with gonadorelin reaching 13.9±12.8 IU/L.
In an observational study in humans, all girls with central precocious puberty were identified by luteinizing hormone measured 60 minutes after gonadorelin administration. In the same human observational study, single-time-point luteinizing hormone measurements for gonadorelin peaked at 60 minutes and showed high concordance with serial sampling.
In girls with central precocious puberty, gonadorelin and triptorelin both significantly raised luteinizing hormone, reaching similar peak levels (13.9±12.8 vs. 12.8±12.1 IU/L). In these girls, gonadorelin's luteinizing hormone response peaked at 30 minutes, whereas triptorelin's response peaked later. In the same group, triptorelin produced significantly higher FSH peaks than gonadorelin, while LH peaks were comparable, so FSH/LH ratios were higher after triptorelin.
In this animal study in cows, pregnancy per artificial insemination (AI) was 50.0% with gonadorelin acetate and 48.1% with buserelin acetate. The difference between the two groups was not significant (P = 0.31). The authors concluded that the two agonists produced comparable pregnancy per AI when given at progesterone device insertion, and so were equally effective in this setting.
In heifers, LH pulse parameters induced by gonadorelin acetate did not differ between Hereford (Bos taurus) and Brahman (Bos indicus) heifers. However, the gonadorelin acetate-induced LH surge was markedly reduced in Brahman heifers compared to Hereford heifers (P<0.01). So in this study the two breeds did not show a similar LH surge response to gonadorelin acetate.
In one reported observation, gonadorelin was administered to a spayed cat with estrus-like behavior to induce ovulation. Three weeks after administration, serum progesterone was measured at 1.6 ng/ml, which was not consistent with the presence of active luteal tissue.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.